Arbutus Reports First Quarter 2023 Financial Results and Corporate Update
04 mai 2023 07h30 HE
|
Arbutus Biopharma Corporation
Additional AB-729 off-treatment data highlighted in an oral presentation at the Global Hepatitis Summit 2023 Dosed first subject in Phase 1 clinical trial with oral RNA Destabilizer, AB-161 Filed...
Arbutus Provides AB-729 Clinical Data and AB-161 Preclinical Data as Oral Presentations at the Global Hepatitis Summit 2023
27 avr. 2023 03h20 HE
|
Arbutus Biopharma Corporation
Seven patients with cHBV remain off all treatment and continue to maintain low levels of HBV DNA and HBsAg for at least one and half years post- AB-729 treatment AB-161 provides robust anti-HBV...
Arbutus Announces FDA Clinical Hold on IND Application for AB-101, an oral PD-L1 inhibitor
25 avr. 2023 07h30 HE
|
Arbutus Biopharma Corporation
WARMINSTER, Pa., April 25, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company leveraging its extensive...
Arbutus to Report First Quarter 2023 Financial Results and Provide Corporate Update
20 avr. 2023 07h30 HE
|
Arbutus Biopharma Corporation
WARMINSTER, Pa., April 20, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop...
Arbutus to Present AB-729 and AB-161 Data at the Global Hepatitis Summit 2023
18 avr. 2023 16h01 HE
|
Arbutus Biopharma Corporation
Two oral presentations scheduled for Thursday, April 27, 2023 WARMINSTER, Pa., April 18, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical...
Arbutus Biopharma and Genevant Sciences File Patent Infringement Lawsuit Against Pfizer/BioNTech
04 avr. 2023 07h52 HE
|
Arbutus Biopharma Corporation
Companies seek compensation for Pfizer’s and BioNTech’s unlicensed use of patented technologies in COVID-19 mRNA-LNP vaccines WARMINSTER, Pa., April 04, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma...
Arbutus Doses First Subject in Phase 1 Clinical Trial with its Oral RNA Destabilizer, AB-161
16 mars 2023 07h30 HE
|
Arbutus Biopharma Corporation
Initial data expected in the second half of 2023 WARMINSTER, Pa., March 16, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus”), a clinical-stage biopharmaceutical...
Arbutus Presents AB-343 Data at the 36th International Conference on Antiviral Research
14 mars 2023 16h05 HE
|
Arbutus Biopharma Corporation
Antiviral potency, selectivity and favorable PK support further development of AB-343 as potential ritonavir-free oral treatment for COVID-19 and other human coronaviruses WARMINSTER, Pa., March 14,...
Arbutus Reports Fourth Quarter and Year End 2022 Financial Results and Corporate Update
02 mars 2023 07h30 HE
|
Arbutus Biopharma Corporation
Significant progress made advancing proprietary programs in chronic HBV and Coronavirus AB-729 data from multiple Phase 2a combination clinical trials expected in 2023 Initial Phase 1 data for...
Arbutus to Report Fourth Quarter and Year End 2022 Financial Results and Provide Corporate Update
16 févr. 2023 07h30 HE
|
Arbutus Biopharma Corporation
WARMINSTER, Pa., Feb. 16, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop...